Karyopharm Therapeutics Inc. filed a registration statement on May 4 2026 with the U.S. Securities and Exchange Commission, announcing a mixed‑shelf offering that could raise up to $400 million through a combination of common stock, preferred stock, units, and warrants. The filing also includes an at‑the‑market (ATM) facility with Jefferies that can issue up to $100 million of common stock.
The company’s audit report for the year ended December 31 2025 highlighted substantial doubt about its ability to continue as a going concern, underscoring the urgency of the capital raise. Karyopharm’s cash balance fell to $64.1 million from $109.1 million at the end of 2024, and its total revenue for 2025 was $146.1 million, a modest increase from $145.2 million in 2024.
Proceeds from the offering are earmarked for research and development, working capital, and potential strategic initiatives. Management emphasized that the funds will support the company’s late‑stage programs in myelofibrosis (SENTRY trial) and endometrial cancer (XPORT‑EC‑042 trial), as well as ongoing commercial activities for selinexor (XPOVIO) in multiple myeloma.
“As we enter 2026, Karyopharm is approaching a defining period marked by important upcoming clinical milestones and a continued focus on disciplined execution, positioning the Company at a potential inflection point,” said President and CEO Richard Paulson. “While selinexor has established a durable commercial foundation in multiple myeloma within a highly competitive treatment landscape, our late‑stage programs in myelofibrosis and endometrial cancer represent an opportunity to fundamentally expand the impact and scale of our franchise.”
The mixed‑shelf structure allows Karyopharm to issue securities at its discretion over a 12‑month period, providing flexibility to respond to market conditions and funding needs. The ATM facility, capped at $100 million, offers a ready source of equity capital that can be deployed quickly if the company’s liquidity position requires additional support.
Analysts have noted the company’s ongoing financial challenges, but the recent filing signals a proactive approach to securing the capital necessary to sustain its clinical pipeline and commercial growth. The offering reflects the company’s strategy to balance debt and equity financing while maintaining operational flexibility.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.